These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10891912)

  • 21. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study.
    Newman L; Mannix LK; Landy S; Silberstein S; Lipton RB; Putnam DG; Watson C; Jöbsis M; Batenhorst A; O'Quinn S
    Headache; 2001 Mar; 41(3):248-56. PubMed ID: 11264684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Ischemic colitis associated with naratriptan administration].
    Macaigne G; Simon P; Auriault ML; Boivin JF; Froguel E; Chayette C; Cheaib S; Deplus R
    Gastroenterol Clin Biol; 2002 Nov; 26(11):1058-9. PubMed ID: 12483146
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of the prototype serotonin 5-HT(1B/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37) on myocardial reactive hyperemic response in conscious dogs.
    Lynch JJ; Shen YT; Pittman TJ; Anderson KD; Koblan KS; Gould RJ; Regan CP; Kane SA
    Eur J Pharmacol; 2009 Nov; 623(1-3):96-102. PubMed ID: 19766109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence.
    Sheftell F; O'Quinn S; Watson C; Pait D; Winter P
    Headache; 2000 Feb; 40(2):103-10. PubMed ID: 10759909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of naratriptan versus naproxen on daily functioning in the acute treatment of migraine: a randomized, double-blind, double-dummy, crossover study.
    Stronks DL; Tulen JH; Bussmann HB; Mulder LJ; Passchier J
    Headache; 2003 Sep; 43(8):845-52. PubMed ID: 12940805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Headache after frequent use of serotonin agonists zolmitriptan and naratriptan.
    Limmroth V; Kazarawa Z; Fritsche G; Diener HC
    Lancet; 1999 Jan; 353(9150):378. PubMed ID: 9950449
    [No Abstract]   [Full Text] [Related]  

  • 27. Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents.
    Deleu D; Hanssens Y
    Acta Neurol Belg; 1999 Jun; 99(2):85-95. PubMed ID: 10427351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety trial with the 5HT1B/1D agonist avitriptan (BMS-180048) in patients with migraine who have experienced pressure, tightness, and/or pain in the chest, neck, and/or throat following sumatriptan.
    Dahlöf CG; Falk L; Risenfors M; Lewis CP
    Cephalalgia; 1998 Oct; 18(8):546-51. PubMed ID: 9827246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Worsening of transformed migraine with naratriptan as prophylactic treatment.
    Pascual J
    Headache; 2000; 40(7):610-1. PubMed ID: 10940106
    [No Abstract]   [Full Text] [Related]  

  • 30. Restoring migraine sufferers' ability to function normally: a comparison of rizatriptan and other triptans in randomized trials.
    Bussone G; D'Amico D; McCarroll KA; Gerth W; Lines CR
    Eur Neurol; 2002; 48(3):172-7. PubMed ID: 12373035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches.
    de Hoon JN; Willigers JM; Troost J; Struijker-Boudier HA; Van Bortel LM
    Clin Pharmacol Ther; 2000 Oct; 68(4):418-26. PubMed ID: 11061582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial.
    Dowson AJ; Massiou H; Laínez JM; Cabarrocas X
    Cephalalgia; 2002 Jul; 22(6):453-61. PubMed ID: 12133045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee.
    Goadsby PJ; Ferrari MD; Olesen J; Stovner LJ; Senard JM; Jackson NC; Poole PH
    Neurology; 2000 Jan; 54(1):156-63. PubMed ID: 10636142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of age and hemodynamics on myocardial blood flow and flow reserve.
    Czernin J; Müller P; Chan S; Brunken RC; Porenta G; Krivokapich J; Chen K; Chan A; Phelps ME; Schelbert HR
    Circulation; 1993 Jul; 88(1):62-9. PubMed ID: 8319357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of naratriptan in adolescent subjects with a history of migraine.
    Christensen ML; Eades SK; Fuseau E; Kempsford RD; Phelps SJ; Hak LJ
    J Clin Pharmacol; 2001 Feb; 41(2):170-5. PubMed ID: 11210397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxy-tryptamine (5-HT(1B/1D)) receptors.
    Goadsby PJ; Knight Y
    Br J Pharmacol; 1997 Nov; 122(5):918-22. PubMed ID: 9384509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coronary vasodilatory capacity and flow reserve in normal myocardium supplied by bypass grafts late after surgery.
    Campisi R; Czernin J; Karpman HL; Schelbert HR
    Am J Cardiol; 1997 Jul; 80(1):27-31. PubMed ID: 9205015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eletriptan for acute migraine.
    Smith LA; Oldman AD; McQuay HJ; Moore RA
    Cochrane Database Syst Rev; 2001; (3):CD003224. PubMed ID: 11687056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Published and not fully published double-blind, randomised, controlled trials with oral naratriptan in the treatment of migraine: a review based on the GSK Trial Register.
    Tfelt-Hansen PC
    J Headache Pain; 2011 Aug; 12(4):399-403. PubMed ID: 21437713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vasoconstrictive properties of the 5HT1B/1D agonists: response to Dahlöf and Mathew.
    Goldstein D
    Cephalalgia; 1999 Jun; 19(5):536-7. PubMed ID: 10403072
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.